HCM: HUTCHMED (China) Limited Stocks News on May 10, 2025

UPDATE - International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on May 15, 2025

HCM

GlobeNewswire

a day ago

UPDATE - International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on May 15, 2025

HCM

GlobeNewswire

2 days ago

International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on May 15, 2025

HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2025

HCM

GlobeNewswire

16 days ago

HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2025

HUTCHMED Completes Patient Enrollment of a Phase II Registration Study of Savolitinib in Gastric Cancer in China

HCM

GlobeNewswire

18 days ago

HUTCHMED Completes Patient Enrollment of a Phase II Registration Study of Savolitinib in Gastric Cancer in China

$HUTCHMED Announces NMPA Conditional Approval for TAZVERIK® (tazemetostat) for the Treatment of Relapsed or Refractory Follicular Lymphoma$

HCM

GlobeNewswire

2 months ago

HUTCHMED Announces NMPA Conditional Approval for TAZVERIK® (tazemetostat) for the Treatment of Relapsed or Refractory Follicular Lymphoma

HUTCHMED (China) Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag

HCM

Simply Wall St.

2 months ago

HUTCHMED (China) Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag

Intended Retirement of Independent Non-executive Directors and changes of composition of board committees

HCM

GlobeNewswire

2 months ago

Intended Retirement of Independent Non-executive Directors and changes of composition of board committees

HUTCHMED (China) Ltd (HCM) (Q4 2024) Earnings Call Highlights: Achieving Profitability and ...

HCM

GuruFocus.com

2 months ago

HUTCHMED (China) Ltd (HCM) (Q4 2024) Earnings Call Highlights: Achieving Profitability and ...

HUTCHMED Highlights Savolitinib SAVANNAH Phase II and Other Data at European Lung Cancer Congress 2025

HCM

GlobeNewswire

2 months ago

HUTCHMED Highlights Savolitinib SAVANNAH Phase II and Other Data at European Lung Cancer Congress 2025

HUTCHMED Reports 2024 Full Year Results and Provides Business Updates

HCM

GlobeNewswire

2 months ago

HUTCHMED Reports 2024 Full Year Results and Provides Business Updates

HUTCHMED and Innovent Jointly Announce that the FRUSICA-2 Phase II/III Study of Fruquintinib and Sintilimab Combination Has Met its Primary Endpoint in Advanced Renal Cell Carcinoma in China

HCM

GlobeNewswire

2 months ago

HUTCHMED and Innovent Jointly Announce that the FRUSICA-2 Phase II/III Study of Fruquintinib and Sintilimab Combination Has Met its Primary Endpoint in Advanced Renal Cell Carcinoma in China

HUTCHMED (China) (LON:HCM) shareholders have earned a 3.7% CAGR over the last three years

HCM

Simply Wall St.

2 months ago

HUTCHMED (China) (LON:HCM) shareholders have earned a 3.7% CAGR over the last three years

HUTCHMED Announces that it has Completed Enrollment of a Phase II Registration Study of Fanregratinib (HMPL-453) for Intrahepatic Cholangiocarcinoma in China

HCM

GlobeNewswire

2 months ago

HUTCHMED Announces that it has Completed Enrollment of a Phase II Registration Study of Fanregratinib (HMPL-453) for Intrahepatic Cholangiocarcinoma in China

HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee

HCM

GlobeNewswire

2 months ago

HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee

HCM

GlobeNewswire

3 months ago

HUTCHMED to Announce 2024 Final Results

Hutchmed price target raised to $27 from $26 at BofA

HCM

TipRanks

3 months ago

Hutchmed price target raised to $27 from $26 at BofA

HUTCHMED Announces NMPA Full Approval for ORPATHYS® (savolitinib) in China for Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC

HCM

GlobeNewswire

4 months ago

HUTCHMED Announces NMPA Full Approval for ORPATHYS® (savolitinib) in China for Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC

Private equity firms are HUTCHMED (China) Limited's (LON:HCM) biggest owners and were rewarded after market cap rose by UK£120m last week

HCM

Simply Wall St.

4 months ago

Private equity firms are HUTCHMED (China) Limited's (LON:HCM) biggest owners and were rewarded after market cap rose by UK£120m last week

Hutchmed divests 45% interest in Shanghai Hutchison for $608M

HCM

TipRanks

4 months ago

Hutchmed divests 45% interest in Shanghai Hutchison for $608M

HUTCHMED Announces NDA Acceptance in China with Priority Review Status for ORPATHYS® and TAGRISSO® Combination in Lung Cancer Patients with MET amplification After Progression on First-Line EGFR Inhibitor Therapy

HCM

GlobeNewswire

4 months ago

HUTCHMED Announces NDA Acceptance in China with Priority Review Status for ORPATHYS® and TAGRISSO® Combination in Lung Cancer Patients with MET amplification After Progression on First-Line EGFR Inhibitor Therapy

HUTCHMED Announces US$608 million Divestment of Non-Core Joint Venture

HCM

GlobeNewswire

4 months ago

HUTCHMED Announces US$608 million Divestment of Non-Core Joint Venture

HUTCHMED to Receive Milestone Payment from Takeda following First European Reimbursement for FRUZAQLA® (fruquintinib)

HCM

GlobeNewswire

5 months ago

HUTCHMED to Receive Milestone Payment from Takeda following First European Reimbursement for FRUZAQLA® (fruquintinib)

HUTCHMED Announces Breakthrough Therapy Designation in China for ORPATHYS® and TAGRISSO® Combination in Certain Lung Cancer Patients After Disease Progression on EGFR Inhibitor Therapy

HCM

GlobeNewswire

5 months ago

HUTCHMED Announces Breakthrough Therapy Designation in China for ORPATHYS® and TAGRISSO® Combination in Certain Lung Cancer Patients After Disease Progression on EGFR Inhibitor Therapy

Innovent and HUTCHMED Jointly Announce NMPA Conditional Approval for TYVYT® (Sintilimab Injection) in Combination with ELUNATE® (Fruquintinib) for the Treatment of Advanced Endometrial Cancer

HCM

PR Newswire

5 months ago

Innovent and HUTCHMED Jointly Announce NMPA Conditional Approval for TYVYT® (Sintilimab Injection) in Combination with ELUNATE® (Fruquintinib) for the Treatment of Advanced Endometrial Cancer

HUTCHMED and Innovent Jointly Announce NMPA Conditional Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Advanced Endometrial Cancer

HCM

GlobeNewswire

5 months ago

HUTCHMED and Innovent Jointly Announce NMPA Conditional Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Advanced Endometrial Cancer

HUTCHMED Announces Continued Inclusion of ORPATHYS® (savolitinib) in the National Reimbursement Drug List in China at Current Terms

HCM

GlobeNewswire

5 months ago

HUTCHMED Announces Continued Inclusion of ORPATHYS® (savolitinib) in the National Reimbursement Drug List in China at Current Terms

HUTCHMED Announces Launch by Takeda of FRUZAQLA® (fruquintinib) in Japan

HCM

GlobeNewswire

6 months ago

HUTCHMED Announces Launch by Takeda of FRUZAQLA® (fruquintinib) in Japan

HCM

GlobeNewswire

6 months ago

HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee

HUTCHMED Highlights Clinical Data to be Presented at the 2024 ASH Annual Meeting and the 2024 ESMO Asia Congress

HCM

GlobeNewswire

6 months ago

HUTCHMED Highlights Clinical Data to be Presented at the 2024 ASH Annual Meeting and the 2024 ESMO Asia Congress

HUTCHMED to Receive First Commercial Milestone Payment Following Over US$200 Million in FRUZAQLA® (fruquintinib) Sales by Takeda

HCM

GlobeNewswire

6 months ago

HUTCHMED to Receive First Commercial Milestone Payment Following Over US$200 Million in FRUZAQLA® (fruquintinib) Sales by Takeda

HUTCHMED Announces that TAGRISSO® plus ORPATHYS® demonstrated high, clinically meaningful response rate in lung cancer patients with high levels of MET overexpression and/or amplification in SAVANNAH Phase II trial

HCM

GlobeNewswire

7 months ago

HUTCHMED Announces that TAGRISSO® plus ORPATHYS® demonstrated high, clinically meaningful response rate in lung cancer patients with high levels of MET overexpression and/or amplification in SAVANNAH Phase II trial

HUTCHMED (China) Ltd (HCM) (Q2 2024) Earnings Call Highlights: Strong US Sales Propel Growth ...

HCM

GuruFocus.com

7 months ago

HUTCHMED (China) Ltd (HCM) (Q2 2024) Earnings Call Highlights: Strong US Sales Propel Growth ...

HUTCHMED (China) (LON:HCM) shareholders are up 17% this past week, but still in the red over the last three years

HCM

Simply Wall St.

7 months ago

HUTCHMED (China) (LON:HCM) shareholders are up 17% this past week, but still in the red over the last three years

Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing

HCM

GlobeNewswire

7 months ago

Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing

HUTCHMED Announces Japan Approval for FRUZAQLA® (fruquintinib) Received by Takeda

HCM

GlobeNewswire

8 months ago

HUTCHMED Announces Japan Approval for FRUZAQLA® (fruquintinib) Received by Takeda

International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on September 24th and 25th, 2024

HCM

GlobeNewswire

8 months ago

International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on September 24th and 25th, 2024

HCM

GlobeNewswire

8 months ago

International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on September 24th and 25th, 2024

HCM

GlobeNewswire

8 months ago

International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on September 24th and 25th, 2024

HUTCHMED Highlights Clinical Data to be Presented at ESMO Congress 2024 and the 2024 World Conference of Lung Cancer

HCM

GlobeNewswire

8 months ago

HUTCHMED Highlights Clinical Data to be Presented at ESMO Congress 2024 and the 2024 World Conference of Lung Cancer

HUTCHMED Provides Update on Fruquintinib for Second-Line Gastric Cancer in China

HCM

GlobeNewswire

8 months ago

HUTCHMED Provides Update on Fruquintinib for Second-Line Gastric Cancer in China

HUTCHMED (China) Limited (HCM): A Cheap Pharmaceutical Stock to Buy According to Short Sellers

HCM

Insider Monkey

8 months ago

HUTCHMED (China) Limited (HCM): A Cheap Pharmaceutical Stock to Buy According to Short Sellers

HUTCHMED to Host Expert Call to discuss Immune Thrombocytopenia

HCM

GlobeNewswire

9 months ago

HUTCHMED to Host Expert Call to discuss Immune Thrombocytopenia

HUTCHMED Reports 2024 Interim Results and Provides Business Updates

HCM

GlobeNewswire

9 months ago

HUTCHMED Reports 2024 Interim Results and Provides Business Updates

HUTCHMED (China) Limited's (LON:HCM) last week's 6.4% decline must have disappointed private equity firms who have a significant stake

HCM

Simply Wall St.

9 months ago

HUTCHMED (China) Limited's (LON:HCM) last week's 6.4% decline must have disappointed private equity firms who have a significant stake

$HUTCHMED Announces NDA Acceptance in China for Tazemetostat for the Treatment of Relapsed or Refractory Follicular Lymphoma with Priority Review Status$

HCM

GlobeNewswire

10 months ago

HUTCHMED Announces NDA Acceptance in China for Tazemetostat for the Treatment of Relapsed or Refractory Follicular Lymphoma with Priority Review Status

HUTCHMED to Announce 2024 Half-Year Financial Results

HCM

GlobeNewswire

10 months ago

HUTCHMED to Announce 2024 Half-Year Financial Results

Save the Date: HUTCHMED to Present R&D Updates on July 9, 2024

HCM

GlobeNewswire

a year ago

Save the Date: HUTCHMED to Present R&D Updates on July 9, 2024

HUTCHMED Announces European Commission Approval for FRUZAQLA® (fruquintinib) Received by Takeda

HCM

GlobeNewswire

a year ago

HUTCHMED Announces European Commission Approval for FRUZAQLA® (fruquintinib) Received by Takeda

HUTCHMED Highlights Publication of Phase III ESLIM-01 Results in The Lancet Haematology

HCM

GlobeNewswire

a year ago

HUTCHMED Highlights Publication of Phase III ESLIM-01 Results in The Lancet Haematology

HUTCHMED Initiates Phase I Trial of Menin Inhibitor HMPL-506 in Patients with Hematological Malignancies in China

HCM

GlobeNewswire

a year ago

HUTCHMED Initiates Phase I Trial of Menin Inhibitor HMPL-506 in Patients with Hematological Malignancies in China

HUTCHMED Highlights Publication of Phase III FRUTIGA Results in Nature Medicine

HCM

GlobeNewswire

a year ago

HUTCHMED Highlights Publication of Phase III FRUTIGA Results in Nature Medicine

HUTCHMED Highlights Presentations at the 2024 ASCO Annual Meeting

HCM

GlobeNewswire

a year ago

HUTCHMED Highlights Presentations at the 2024 ASCO Annual Meeting

HUTCHMED announces retirement of Chairman, appointment of new Chairman and change of members of board committees

HCM

GlobeNewswire

a year ago

HUTCHMED announces retirement of Chairman, appointment of new Chairman and change of members of board committees

HUTCHMED Highlights Sovleplenib Phase III ESLIM-01 Study and Hematological Malignancy Programs Data to be Presented at the upcoming EHA2024 Congress

HCM

GlobeNewswire

a year ago

HUTCHMED Highlights Sovleplenib Phase III ESLIM-01 Study and Hematological Malignancy Programs Data to be Presented at the upcoming EHA2024 Congress

HUTCHMED Initiates Phase II/III Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naïve Pancreatic Ductal Adenocarcinoma in Collaboration with Hengrui

HCM

GlobeNewswire

a year ago

HUTCHMED Initiates Phase II/III Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naïve Pancreatic Ductal Adenocarcinoma in Collaboration with Hengrui

$HUTCHMED Initiates the RAPHAEL Registrational Phase III Trial of HMPL-306 for Patients with IDH1- and/or IDH2-Mutated Relapsed/Refractory Acute Myeloid Leukemia in China$